Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

229
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
229
Multiple Comparison Tests01:13

Multiple Comparison Tests

4.0K
Multiple comparison test, abbreviated as MCT, is a post hoc analysis generally performed after comparing multiple samples with one or more tests. An MCT will help identify a significantly different sample among multiple samples or a factor among multiple factors.
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
4.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
The Mantel-Cox Log-Rank Test01:19

The Mantel-Cox Log-Rank Test

446
The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of...
446
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

3.4K
A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
3.4K
Receiver Operating Characteristic Plot01:15

Receiver Operating Characteristic Plot

285
A ROC (Receiver Operating Characteristic) plot is a graphical tool used to assess the performance of a binary classification model by illustrating the trade-off between sensitivity (true positive rate) and specificity (false positive rate). By plotting sensitivity against 1 - specificity across various threshold settings, the ROC curve shows how well the model distinguishes between classes, with a curve closer to the top-left corner indicating a more accurate model. The area under the ROC curve...
285

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China.

Frontiers in urology·2026
Same author

A case of SAPHO syndrome with wrist involvement as the first presentation and response to tofacitinib therapy.

Joint bone spine·2025
Same author

Corrigendum: A retrospective study of paraganglioma of the urinary bladder and literature review.

Frontiers in surgery·2025
Same author

Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study.

Signal transduction and targeted therapy·2024
Same author

[Retracted] Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.

Oncology reports·2024
Same author

A retrospective study of paraganglioma of the urinary bladder and literature review.

Frontiers in surgery·2024

相关实验视频

Updated: Jul 28, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K

的直接预后比较的直接预后比较.

Zhen Liang1, Chen Yuliang1, Ming Zhu1

  • 1Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

European journal of medical research
|June 2, 2023
PubMed
概括

与激进前列腺切除术 (RP) 相比,低剂量率支臂治疗 (LDR) 对中等风险前列腺癌 (IRPC) 患者提供了改善的无复发生化生存率 (bRFS),具有类似的整体生存率.

关键词:
效果的比较性 效果的比较低剂量率支臂疗法是一种低剂量率支臂疗法.前列腺新生体前列腺瘤.进行激进的前列腺切除术.治疗结果的结果.

更多相关视频

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K

相关实验视频

Last Updated: Jul 28, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K

科学领域:

  • 泌尿器科 泌尿器科 泌尿器科 泌尿器科
  • 在瘤学瘤学.
  • 辐射瘤学 辐射瘤学

背景情况:

  • 中期风险前列腺癌 (IRPC) 需要仔细选择治疗.
  • 激进前列腺切除术 (RP) 和低剂量率支臂治疗 (LDR) 是IRPC的主要治疗选择.

研究的目的:

  • 在IRPC患者中比较RP和LDR之间的临床结果.
  • 评估生化无复发存活率 (bRFS),临床无复发存活率 (cRFS),癌症特异性存活率 (CSS) 和整体存活率 (OS).

主要方法:

  • 在2014年至2021年期间接受治疗的361名IRPC患者的回顾性分析.
  • 160名接受RP治疗的患者与201名接受-125LDR治疗的患者进行了比较.
  • 统计分析包括日志等级测试和康克斯回归用于生存结果.

主要成果:

  • 与RP相比,LDR显示5年 (83.2%对70.2%) 和8年 (68.9%对63.1%) 的bRFS显著更高.
  • 在RP和LDR组之间没有观察到cRFS,CSS或OS的显著差异.
  • 更糟糕的bRFS的独立预测因素包括前列腺体积≤30毫升,阳性手术边缘和>50%的阳性活检核心.

结论:

  • 低剂量率支臂疗法 (LDR) 是中等风险前列腺癌 (IRPC) 的可行的治疗方法.
  • 与激进前列腺切除术 (RP) 相比,LDR提供了优越的bRFS.
  • 在IRPC患者中,LDR实现了与RP相比的cRFS,CSS和OS率.